Delivery Order SPE2DB25D3017-SPE2DB25FVKTA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Calquence 100 mg tablets (60-count units) with a ceiling value of $11,187.56. This firm fixed-price delivery order, with an ultimate completion date of September 15, 2025, represents a competitive award with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Calquence 100 mg tablets (60-count units) with a ceiling value of $5,593.77. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and was competitively awarded without set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Calquence 100 mg tablets (60-count units) under a firm fixed-price contract. The delivery order, valued at $5,593.77 with an ultimate completion date of October 21, 2025, represents a non-competitive, non-set-aside award supporting federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Calquence 100 mg tablets (60-count units) with a ceiling value of $16,781.31. This firm fixed-price delivery order, which is not set-aside and represents a competitive award, is scheduled for ultimate completion by September 16, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $5,593.77 to AmerisourceBergen Drug Corp for Calquence 100 mg tablets (60-count units) on August 19, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Calquence 100 mg tablets (60-count units) under a firm fixed-price contract valued at $33,562.68, with completion scheduled for October 21, 2025. This non-set-aside award represents a competitive procurement action, consistent with AmerisourceBergen's established role as a critical pharmaceutical supplier to federal medical systems. The contract is performed at the...
- The Defense Logistics Agency awarded a $11,187.56 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Calquence 100 mg tablets (60-count units). The contract is firm fixed price with no set-aside designation and is scheduled for completion by September 30, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Calquence 100 mg tablets (60-count units) with a contract ceiling value of $5,593.77. This is a firm fixed-price delivery order with an ultimate completion date of September 5, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $5,593.77 to AmerisourceBergen Drug Corp for Calquence 100 mg tablets (60-count units) on August 20, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,593.77 on August 1, 2025, for the supply of Calquence 100 mg tablets (60 count). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 22, 2025, and performance to be fulfilled at the company's Conshohocken, Pennsylvania facility. The delivery order represents a child contract under AmerisourceBergen's broader relationship with DLA, leveraging the company's...
- SPE2DB25D3017Indefinite Delivery Contract
- SPE2DB25D3017-SPE2DB25FVKTADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Calquence 100 mg tablets (60-count units) with a contract value of $5,593.77 and a completion date of October 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, executed under open competition. The place of performance is the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through its extensive portfolio of brand-name and generic medications, vaccines, and medical supplies. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime contract vehicle enables comprehensive global pharmaceutical support across multiple therapeutic domains to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The company's consistent track record of competitively awarded federal contracts demonstrates its capability to fulfill diverse medical supply requirements across varying transaction values, positioning it as a key pharmaceutical prime vendor within the DLA's medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 9/19/25 |